FIRAZYR 30 mg, solution for injection in a pre-filled syringe syringe, 3 ml
Active ingredients: Icatibant acetate, Icatibant
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 3 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FIRAZYR 30 mg, solution injectable en seringue pré-remplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 3 ml avec aiguille(s)
- Marketing authorisation holder
- TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Nov 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61680479CIP73873680CIP133400938736809Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ACÉTATE D'ICATIBANTsolution | — | SA |
| ICATIBANTsolution | 30 mg · une seringue préremplie de 3 ml | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.